Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs
It is impossible to conduct head-to-head trials of all the therapies to determine optimal treatment in the rapidly advancing era of therapies for metastatic renal cell carcinoma (mRCC). In this network meta-analysis,we aimed to compare efficacy and safety of first-line treatments for mRCC. We search...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Impact Journals LLC
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941278/ |
| id |
pubmed-4941278 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-49412782016-07-19 Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs Chang, Xiaofeng Zhang, Fan Liu, Tieshi Yang, Rong Ji, Changwei Zhao, Xiaozhi Xu, Linfeng Liu, Guangxiang Guo, Hongqian Research Paper It is impossible to conduct head-to-head trials of all the therapies to determine optimal treatment in the rapidly advancing era of therapies for metastatic renal cell carcinoma (mRCC). In this network meta-analysis,we aimed to compare efficacy and safety of first-line treatments for mRCC. We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and unpublished studies were also sought through “clinicaltrials.gov” from their inception through January 31, 2016. A database search identified 1253 articles, with 11 studies meeting the eligibility criteria. A total of 7597 patients in twelve different treatment arms were assessed. Network meta-analysis showed sunitinib had a significantly longer PFS than IFN-α (SMD=−5.68; 95%CI: −10.76,−0.86; P<0.001) and placebo (SMD=−6.71; 95%CI: −12.65,−0.79; P<0.001), meanwhile, pazopanib had a significantly longer PFS compared with placebo (SMD=5.13; 95%CI: 0.43, 10.09; P<0.001). The cumulative ranking probability curve indicated that sunitinib had the highest probability of being the best treatment modality in terms of PFS and it also had the highest probability of being the safest drugs as the first-line treatment when it came to SAE. Thus, sunitinib might be the best choice of first-line treatment for patients with mRCC because it has the most favorable balance between efficacy and safety. Impact Journals LLC 2016-02-19 /pmc/articles/PMC4941278/ /pubmed/26908455 http://dx.doi.org/10.18632/oncotarget.7511 Text en Copyright: © 2016 Chang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Chang, Xiaofeng Zhang, Fan Liu, Tieshi Yang, Rong Ji, Changwei Zhao, Xiaozhi Xu, Linfeng Liu, Guangxiang Guo, Hongqian |
| spellingShingle |
Chang, Xiaofeng Zhang, Fan Liu, Tieshi Yang, Rong Ji, Changwei Zhao, Xiaozhi Xu, Linfeng Liu, Guangxiang Guo, Hongqian Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs |
| author_facet |
Chang, Xiaofeng Zhang, Fan Liu, Tieshi Yang, Rong Ji, Changwei Zhao, Xiaozhi Xu, Linfeng Liu, Guangxiang Guo, Hongqian |
| author_sort |
Chang, Xiaofeng |
| title |
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs |
| title_short |
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs |
| title_full |
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs |
| title_fullStr |
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs |
| title_full_unstemmed |
Comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 RCTs |
| title_sort |
comparative efficacy and safety of first-line treatments in patients with metastatic renal cell cancer: a network meta-analysis based on phase 3 rcts |
| description |
It is impossible to conduct head-to-head trials of all the therapies to determine optimal treatment in the rapidly advancing era of therapies for metastatic renal cell carcinoma (mRCC). In this network meta-analysis,we aimed to compare efficacy and safety of first-line treatments for mRCC. We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and unpublished studies were also sought through “clinicaltrials.gov” from their inception through January 31, 2016. A database search identified 1253 articles, with 11 studies meeting the eligibility criteria. A total of 7597 patients in twelve different treatment arms were assessed. Network meta-analysis showed sunitinib had a significantly longer PFS than IFN-α (SMD=−5.68; 95%CI: −10.76,−0.86; P<0.001) and placebo (SMD=−6.71; 95%CI: −12.65,−0.79; P<0.001), meanwhile, pazopanib had a significantly longer PFS compared with placebo (SMD=5.13; 95%CI: 0.43, 10.09; P<0.001). The cumulative ranking probability curve indicated that sunitinib had the highest probability of being the best treatment modality in terms of PFS and it also had the highest probability of being the safest drugs as the first-line treatment when it came to SAE. Thus, sunitinib might be the best choice of first-line treatment for patients with mRCC because it has the most favorable balance between efficacy and safety. |
| publisher |
Impact Journals LLC |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941278/ |
| _version_ |
1613607646433116160 |